HER2 CR

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Oct 16, 2025 → Oct 28, 2026

Cited window

Oct 16, 2025 → Oct 26, 2026

Retrieved

Nov 1, 2026

Title

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment

Registry

NCT06663787

Study IDs

HER2 CR · 80-24-0057 (Nagoya City Unversity)

Sponsor

Nagoya City University

Design

Observational · Observational, cohort, prospective

Status

Active, not recruiting

Enrollment

50 estimated

Registered

2024-10-29

Start

2024-04-01 actual

Primary completion

2026-12-31 estimated

Primary endpoint

The status of ctDNA

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –Commentary on ctDNA status and subsequent outcomes, limitations of conventional disease assessment, and the evidence needed to establish clinical utility is not fully covered. This report should not be used to infer that those views were absent from the sources.
• –The full HER2-CR results article and a separate protocol were not available. Reported numerical findings are attributed summaries rather than an independently assessed full results report; registry material describes planned assessments.
• –Drug-label material was unavailable. The adverse-effect comments should be read as a speaker's regimen description, not a comprehensive safety assessment or a comparison of stopping versus continuing treatment.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –No individual is identified for the BC Tube statements. Presentation relays, reposts and repeated quoted posts should not be counted as additional independent clinical opinions.
• –The broader recordings discuss related monitoring and treatment-duration questions, including separate datasets and Stop HER2. Their findings, eligibility descriptions and expected reporting timelines must not be transferred to HER2-CR, and different source dates do not establish a change of mind.
• –The treatment-continuation examples are not a complete account of maintenance alternatives or decisions after focal progression.

How reports are built and checked: Methods.

Last checked for new commentary Nov 1, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "HER2 CR" (NCT06663787), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "her2-cr-06663787". If you cannot make requests, read https://www.erudio.com/reports/her2-cr-nct06663787.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06663787", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06663787 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/her2-cr-nct06663787.json
curl https://www.erudio.com/reports/her2-cr-nct06663787.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "her2-cr-06663787" })